IRIS UniCatt

Ciccullo, Arturo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 936
EU - Europa 609
AS - Asia 399
SA - Sud America 84
AF - Africa 11
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.045
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 921
SE - Svezia 205
CN - Cina 144
SG - Singapore 131
IT - Italia 112
FR - Francia 80
BR - Brasile 78
DE - Germania 77
IN - India 59
IE - Irlanda 44
ID - Indonesia 28
RU - Federazione Russa 17
FI - Finlandia 14
CA - Canada 13
GB - Regno Unito 11
BE - Belgio 10
KR - Corea 8
NL - Olanda 8
UA - Ucraina 8
PL - Polonia 7
ES - Italia 5
CH - Svizzera 4
TR - Turchia 4
AE - Emirati Arabi Uniti 3
BD - Bangladesh 3
IR - Iran 3
JP - Giappone 3
TW - Taiwan 3
ZA - Sudafrica 3
AR - Argentina 2
AT - Austria 2
AU - Australia 2
CI - Costa d'Avorio 2
CL - Cile 2
EU - Europa 2
NZ - Nuova Zelanda 2
TZ - Tanzania 2
YE - Yemen 2
BO - Bolivia 1
CM - Camerun 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
HK - Hong Kong 1
IQ - Iraq 1
JM - Giamaica 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
UZ - Uzbekistan 1
VN - Vietnam 1
ZW - Zimbabwe 1
Totale 2.045
Salva come PNG Salva come JPEG
Città #
Chandler 314
Singapore 77
Ashburn 74
New York 63
Dublin 44
San Mateo 36
Beijing 34
Jakarta 28
Princeton 28
Rome 28
Boston 27
Wilmington 27
Nanjing 21
Dearborn 17
Marseille 17
Redwood City 16
Cattolica 14
Helsinki 13
Los Angeles 11
Milan 11
Brussels 10
Moscow 10
The Dalles 10
Chicago 8
Fairfield 8
Hefei 8
Pune 8
Changsha 7
Frankfurt am Main 7
Guangzhou 6
Shenyang 6
Hangzhou 5
Jacksonville 5
Jinan 5
Nanchang 5
Seattle 5
São Paulo 5
Toronto 5
Belo Horizonte 4
Busto Arsizio 4
Falkenstein 4
Jiaxing 4
Munich 4
Nuremberg 4
Ottawa 4
Paris 4
Seoul 4
Zurich 4
Alcalá de Henares 3
Ann Arbor 3
Augusta 3
Belford Roxo 3
Kunming 3
Leawood 3
London 3
Mumbai 3
Santa Clara 3
Tianjin 3
Warsaw 3
Abidjan 2
Amsterdam 2
Ardabil 2
Busan 2
Cambridge 2
Campinas 2
Chengdu 2
Dar es Salaam 2
Fuzhou 2
Genoa 2
Guarulhos 2
Hebei 2
Hyderabad 2
Kraków 2
Lauterbourg 2
Montreal 2
Mountain View 2
Porto Alegre 2
Redmond 2
Rizziconi 2
Roubaix 2
San Francisco 2
Sanaa 2
Tokyo 2
Trezzo sull'Adda 2
Vancouver 2
Vienna 2
Woodbridge 2
Wuhan 2
Agudos 1
Almaty 1
Andover 1
Andrelândia 1
Anápolis 1
Auckland 1
Açu 1
Baghdad 1
Baltimore 1
Bangalore 1
Barreiros 1
Bauru 1
Totale 1.166
Salva come PNG Salva come JPEG
Nome #
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 116
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 101
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 94
Shall we dance? Extending tango's results to clinical practice 91
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 88
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 86
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 84
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 80
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 80
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 78
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice 77
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 73
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 73
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 73
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 72
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 71
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 68
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 65
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 65
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice 63
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 62
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 61
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 58
Dolutegravir plus lamivudine for the treatment of HIV-1 infection 58
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study 56
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 55
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 55
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 52
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 50
Totale 2.105
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.968
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.968
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020100 0 0 0 0 0 0 0 0 0 0 94 6
2020/2021103 6 1 4 2 8 4 4 2 6 26 31 9
2021/2022282 29 2 7 46 9 5 5 42 6 22 37 72
2022/2023684 102 96 63 106 39 71 33 57 78 2 25 12
2023/2024308 14 78 6 35 6 93 15 1 4 11 17 28
2024/2025433 13 11 41 30 71 24 25 26 63 39 90 0
Totale 2.105